Chargement en cours...
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
There are five tyrosine kinase inhibitors (TKIs) that are currently approved (in the European Union and the United States) for the treatment of chronic myeloid leukaemia (CML) in the chronic phase (CP) and each of them has its own efficacy and toxicity profile. Oral ponatinib (Iclusig(®)) is a third...
Enregistré dans:
| Publié dans: | Ther Adv Hematol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6399752/ https://ncbi.nlm.nih.gov/pubmed/30854182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719826444 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|